» Articles » PMID: 36068658

Refractory Wounds Induced by Normal-renal Calciphylaxis: An Under-recognised Calcific Arteriolopathy

Overview
Journal Int Wound J
Date 2022 Sep 7
PMID 36068658
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Normal-renal calciphylaxis (NRC) is a devastating calcific vasculopathy characterised by refractory wounds. It is more likely to be misdiagnosed because of the absence of renal insufficiency. Failure to effectively control may lead to rapid deterioration and ultimately death. However, current knowledge of it is still inadequate.

Objectives: To provide a relatively comprehensive review of NRC.

Methods: Nine electronic medical databases including PubMed, Web of Science, Embase, the Cochrane Library and so on were searched from inception to April 1, 2022. Articles in which calciphylaxis was diagnosed in patients with normal renal function were included.

Results: Totally 140 articles were retrieved with 187 patients (median age, 62 years [IQR, 49.63 ~ 75.70 years]; 83.42% female; 84.5% Caucasian). Vitamin K antagonism (43.32%) and diabetes (39.57%) accounted for most of the concomitant factors. Cutaneous presentations were the most common. Pathological confirmation was made in 97.86% of patients with an accuracy of 99.45%. Multidisciplinary therapeutic strategies were usually implemented while the final prognosis was not ideal, with a 6-month mortality rate of 21.10% and a 1-year mortality rate of 27.52%.

Conclusion: NRC is an under-recognised disease caused by a variety of factors; meanwhile, multidisciplinary efforts are required to inform diagnostic and therapeutic decisions.

Citing Articles

Advanced Calciphylaxis in a Patient With End-Stage Renal Disease: A Case Report Highlighting Diagnostic and Therapeutic Challenges in Late-Stage Presentation.

Chaganlal P, Kalandoor V, Jones D, Pace C, Silver S Cureus. 2024; 16(9):e68866.

PMID: 39246637 PMC: 11380459. DOI: 10.7759/cureus.68866.


Refractory wounds induced by normal-renal calciphylaxis: An under-recognised calcific arteriolopathy.

Wu J, Chen L, Dang F, Zha P, Li R, Ran X Int Wound J. 2022; 20(4):1262-1275.

PMID: 36068658 PMC: 10031205. DOI: 10.1111/iwj.13951.

References
1.
Budisavljevic M, Cheek D, Ploth D . Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996; 7(7):978-82. DOI: 10.1681/ASN.V77978. View

2.
Brandenburg V, Evenepoel P, Floege J, Goldsmith D, Kramann R, Massy Z . Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. Nephrol Dial Transplant. 2016; 31(8):1211-9. DOI: 10.1093/ndt/gfw025. View

3.
Gabel C, Blum A, Francois J, Chakrala T, Dobry A, Garza-Mayers A . Clinical mimickers of calciphylaxis: A retrospective study. J Am Acad Dermatol. 2021; 85(6):1520-1527. DOI: 10.1016/j.jaad.2021.03.035. View

4.
Maverakis E, Marzano A, Le S, Callen J, Bruggen M, Guenova E . Pyoderma gangrenosum. Nat Rev Dis Primers. 2020; 6(1):81. DOI: 10.1038/s41572-020-0213-x. View

5.
Honda Y, Endo Y, Tanizaki H, Fujisawa A, Kitoh A, Miyachi Y . Calciphylaxis associated with acute renal failure in multicentric Castleman's disease. Eur J Dermatol. 2015; 25(5):497-9. DOI: 10.1684/ejd.2015.2627. View